Jett Crowdis

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Table S4 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>

  2026-06-17

• Supplementary Figure S1 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>

  2026-06-17

• Supplementary Figure S3 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>

  2026-06-17

• Supplementary Figure S6 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>

  2026-06-17

• Supplementary Table S1 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>

  2026-06-17

• Supplementary Table S2 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>

  2026-06-17

• Supplementary Table S3 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>

  2026-06-17

• Data from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>

  2026-06-17

• Supplementary Figure S4 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>

  2026-06-17

• Supplementary Figure S2 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>

  2026-06-17

• Supplementary Figure S5 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>

  2026-06-17

• Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer

  npj Precision Oncology · 2026-04-28

• Supplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

  2025-11-25

• Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

  2025-11-25

• Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

  2025-11-25

• Abstract B098: Global-scale patient-partnered genomic databanking: unlocking therapeutic and biological insights in rare cancers through decentralized recruitment and open data sharing

  Cancer Epidemiology Biomarkers & Prevention · 2025-09-18

• Abstract B035: Deep learning-based spatially resolved immune clustering in the tumor microenvironment predicts distant metastasis risk in high-grade prostate cancer

  Clinical Cancer Research · 2025-07-10

• Immune Spatial Organization Predicts Metastasis Risk in Aggressive Localized Prostate CancerPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-05-19 · 1 citations

• Dissecting tumor cell programs through group biology estimation in clinical single-cell transcriptomics

  Nature Communications · 2025-03-01

• Rare germline structural variants increase risk for pediatric solid tumors

  Science · 2025-01-02 · 18 citations